IRA Reality Check: Adapting Hub and Copay Programs to Ensure Patient Access and Affordability
Live Event | September 17, 2024 | 1pm EDT
Register to join us live or get on-demand access
The IRA is here to stay. How can brand and access leaders adapt?
The IRA (Inflation Reduction Act) is much more than a passing threat. As key provisions are proceeding, it is looking less likely that the IRA will be challenged in congress. Manufacturers may need to consider multiple different adjustments to bolster branded patient support programming.
As the industry grapples with the realities of price negotiations, inflation penalties, and Part D redesign, manufacturers must adapt their hub and copay programs to ensure continued patient access and affordability.
The IRA may have rewritten the rulebook, but with strategic adaptations and a patient-centric focus, manufacturers can continue to deliver effective patient support programs that meet the evolving needs of patients in this new era of drug pricing.
Join ConnectiveRx for an in-depth look at how brand and access leaders can continue to offer robust patient support despite the challenges brought about by the IRA.
Register for live and on-demand access!
Featuring a conversation with:
Partner, Healthcare Privacy and Cybersecurity
Bill Sarraille is the founder of Sarraille & Associates, a life sciences regulatory consultancy. S&A works with patient groups and rare disease manufacturers on coverage, reimbursement, cost sharing, and access issues.
In addition, Bill is a policy adviser to the HIV and Hepatitis and Policy Institute and to FSHD Society, the patient group focused on a muscular dystrophy which has affected Bill and 5 generations of his family. He also is a compliance adviser to Accessia Health, which is a 501(c)(3) that assists patients with cost sharing needs. Further, Bill is the General Counsel of the Pharmaceutical Coalition for Patient Access, which is a charitable organization dedicated to launching a mechanism to assist Medicare patients battling cancer. Bill is on the board of directors for both the FSHD Society and Kalderos, a health IT firm.
Finally, Bill is an Adjunct Professor at the University of Maryland Francis King Carey School of Law where he teaches pharmaceutical law.
Bill practiced health care law for 34 years, many of those years at Sidney Austin, where he was a Senior Partner in the Health Care and Life Sciences Practices, before his retirement in January. During his law practice, Bill represented ConnectiveRx.